Agoitrous Graves’ Hyperthyroidism with Markedly Elevated Thyroid Stimulating Immunoglobulin Titre displaying Rapid Response to Carbimazole with Discordant Thyroid Function
- Author:
Yin Chian Kon
1
;
Brenda Su Ping Lim
1
;
Yingshan Lee
1
;
Swee Eng Aw
2
;
Yoko Kin Yoke Wong
3
Author Information
- Publication Type:Case Reports
- Keywords: responsiveness;
- MeSH: carbimazole; Thyroid Stimulating Immunoglobulin; Immunoglobulins, Thyroid-Stimulating; Immunologic Tests; Graves disease
- From: Journal of the ASEAN Federation of Endocrine Societies 2020;35(2):224-232
- CountryPhilippines
- Language:English
- Abstract: We characterize the clinical and laboratory characteristics of 5 patients with Graves’ thyrotoxicosis whose serum free thyroxine (fT4) concentration decreased unexpectedly to low levels on conventional doses of carbimazole (CMZ) therapy. The initial fT4 mean was 40.0 pM, range 25-69 pM. Thyroid volume by ultrasound measured as mean 11 ml, range 9.0-15.6 ml. Initial TSI levels measured 1487% to >4444%. Serum fT4 fell to low-normal or hypothyroid levels within 3.6 to 9.3 weeks of initiating CMZ 5 to 15 mg daily, and subsequently modulated by fine dosage adjustments. In one patient, serum fT4 fluctuated in a “yo-yo” pattern. There also emerged a pattern of low normal/low serum fT4 levels associated with discordant low/mid normal serum TSH levels respectively, at normal serum fT3 levels. The long-term daily-averaged CMZ maintenance dose ranged from 0.7 mg to 3.2 mg. Patients with newly diagnosed Graves' hyperthyroidism who have small thyroid glands and markedly elevated TSI titres appear to be “ATD dose sensitive.” Their TFT on ATD therapy may display a “central hypothyroid” pattern. We suggest finer CMZ dose titration at closer follow-up intervals to achieve biochemical euthyroidism.
- Full text:913-Article Text-11629-2-10-20201129.pdf
